Perkins Capital Management’s Champions Oncology CSBR Stock Holding History

Perkins Capital Management’s Portfolio CSBR Stock Details CSBR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$152K	Sell	20,500 -17,500	-46%	-$122K	0.18%	76
2019 Q4	$317K	Sell	38,000 -27,500	-42%	-$170K	0.28%	78
2019 Q3	$370K	Sell	65,500 -77,050	-54%	-$500K	0.32%	76
2019 Q2	$1.12M	Sell	142,550 -32,150	-18%	-$282K	0.78%	36
2019 Q1	$1.71M	Hold	174,700	–	–	1.13%	25
2018 Q4	$1.36M	Sell	174,700 -5,900	-3%	-$67.8K	1.06%	26
2018 Q3	$3.15M	Buy	180,600 +77,600	+75%	+$691K	1.89%	9
2018 Q2	$653K	Buy	+103,000	New	+$495K	0.47%	69

Other funds holding CSBR

BPI

Battery Partners IX Boston, Massachusetts $22.4M AUM 27.71% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

CPA

Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

CCM

Cadence Capital Management Boston, Massachusetts $415M AUM 11.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Perkins Capital Management's CSBR Position: Q1 2020 in Review

Perkins Capital Management reduced its Champions Oncology (CSBR) stake by 46% in Q1 2020, selling an estimated $122K and leaving 20,500 shares worth $152K. The position accounts for 0.18% of the portfolio, ranked #76.

Perkins Capital Management first reported a position in CSBR in Q2 2018 and has held it in 8 quarters since. The position peaked at $3.15M in Q3 2018. 32 funds tracked by Wall St. Rank hold CSBR as of Q1 2020.

Perkins Capital Management held 20,500 shares of Champions Oncology worth $152K as of Q1 2020.
Perkins Capital Management sold 17,500 Champions Oncology shares in Q1 2020, an estimated $122K.
Champions Oncology made up 0.18% of Perkins Capital Management's portfolio in Q1 2020, its #76 holding.
Perkins Capital Management first reported a position in Champions Oncology in Q2 2018 and has held it in 8 quarters since.
Perkins Capital Management's Champions Oncology position peaked at $3.15M in Q3 2018.
32 funds tracked by Wall St. Rank held Champions Oncology as of Q1 2020.

Based on Perkins Capital Management's 13F filing for Q1 2020, filed 29 Apr 2020.